• NEBANNER

Special Design for Rivaroxaban And Prasugrel Etc - Hydroxypyrazolodpyrimidine pyrazolo(3,4-d)pyrimidin-1-ol – JIN DUN

Special Design for Rivaroxaban And Prasugrel Etc - Hydroxypyrazolodpyrimidine pyrazolo(3,4-d)pyrimidin-1-ol – JIN DUN

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We rely upon strategic thinking, constant modernisation in all segments, technological advances and of course upon our employees that directly participate in our success for Diy Crystal Glue Jewelry, Well Water Treatment, Circulatory Problems, Together with our efforts, our products and solutions have won the trust of clients and been very salable each here and abroad.
Special Design for Rivaroxaban And Prasugrel Etc - Hydroxypyrazolodpyrimidine pyrazolo(3,4-d)pyrimidin-1-ol – JIN DUN Detail:

It is clinically used in primary and secondary Hyperuricemia, especially in patients with hyperuricemia, as well as in patients with renal insufficiency, and in patients with recurrent or chronic gout, as well as in patients with Hyperuricemia. Used in patients with Gouty nephropathy to relieve symptoms and reduce the formation of renal uric acid stones; gout stones; used in uric acid kidney stones and uric acid kidney disease.

This product and its metabolites can inhibit xanthine oxidase, so that hypoxanthine and xanthine cannot be converted into uric acid, that is, the synthesis of uric acid is reduced, thereby reducing the concentration of uric acid in the blood and reducing the concentration of urate in the bones, Joints and kidneys, drugs that can inhibit the synthesis of uric acid. This product can inhibit the activity of liver drug enzymes.

(1) . Primary and secondary hyperuricemia, especially those with excessive uric acid production, are also used for hyperuricemia with renal insufficiency;

(2) . For the treatment of gout, suitable for recurrent or chronic gout. For patients with gouty nephropathy, it can relieve symptoms and reduce the formation of uric acid stones in the kidneys;

(3) . Tophi;

(4) . Used for uric acid kidney stones and (or) uric acid nephropathy.

Standard:usp42
Assay:98-102%

Exterior:White or almost white powder
Package : 25kg/bag

There is bone marrow suppression, which can cause pancytopenia, and the drug should be discontinued if necessary. Drink plenty of water during the medication, and make the urine neutral or alkaline to excrete diuretic acid. This product must be applied after the acute inflammation of gouty arthritis disappears (usually about two weeks after the onset). During medication, blood picture and liver and kidney function should be checked regularly.


Product detail pictures:

Special Design for Rivaroxaban And Prasugrel Etc - Hydroxypyrazolodpyrimidine pyrazolo(3,4-d)pyrimidin-1-ol – JIN DUN detail pictures


Related Product Guide:

With our leading technology also as our spirit of innovation,mutual cooperation, benefits and development, we are going to build a prosperous future jointly with your esteemed company for Special Design for Rivaroxaban And Prasugrel Etc - Hydroxypyrazolodpyrimidine pyrazolo(3,4-d)pyrimidin-1-ol – JIN DUN , The product will supply to all over the world, such as: luzern, Jamaica, Macedonia, Our business activities and processes are engineered to make sure our customers have access to widest range of products with the shortest supply time lines. This achievement is made possible by our highly skilled and experienced team. We look for people who want to grow with us around the globe and stand out from the crowd. We now have people who embrace tomorrow, have vision, love stretching their minds and going far beyond what they thought was achievable.
  • We have been cooperated with this company for many years, the company always ensure timely delivery ,good quality and correct number, we are good partners.
    5 Stars By Christine from Durban - 2018.12.11 14:13
    The company leader recept us warmly, through a meticulous and thorough discussion, we signed a purchase order. Hope to cooperate smoothly
    5 Stars By Cindy from Riyadh - 2018.06.26 19:27
    Write your message here and send it to us